Seven Grand Managers LLC Invests $2.89 Million in Capricor Therapeutics, Inc. $CAPR

Posted by Brenda Bartman on May 28th, 2026

Seven Grand Managers LLC purchased a new position in shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR – Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 100,000 shares of the biotechnology company’s stock, valued at approximately $2,886,000.

Other institutional investors have also recently added to or reduced their stakes in the company. GoalVest Advisory LLC acquired a new position in Capricor Therapeutics in the 4th quarter valued at about $59,000. Allworth Financial LP raised its stake in Capricor Therapeutics by 5,021.5% in the 4th quarter. Allworth Financial LP now owns 3,329 shares of the biotechnology company’s stock valued at $96,000 after purchasing an additional 3,264 shares during the last quarter. Russell Investments Group Ltd. raised its stake in Capricor Therapeutics by 122.2% in the 3rd quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 2,786 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in Capricor Therapeutics by 280.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company’s stock valued at $67,000 after purchasing an additional 4,976 shares during the last quarter. Finally, ProShare Advisors LLC acquired a new position in Capricor Therapeutics in the 4th quarter valued at about $203,000. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics Price Performance

CAPR opened at $29.14 on Thursday. The stock has a market capitalization of $1.69 billion, a price-to-earnings ratio of -12.56 and a beta of 0.48. The business has a 50-day moving average of $31.54 and a two-hundred day moving average of $25.62. Capricor Therapeutics, Inc. has a 12 month low of $4.30 and a 12 month high of $40.37.

Capricor Therapeutics (NASDAQ:CAPR – Get Free Report) last posted its quarterly earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.04). Equities research analysts anticipate that Capricor Therapeutics, Inc. will post -0.75 earnings per share for the current year.

Insider Activity

In other Capricor Therapeutics news, CFO Anthony Bergmann sold 25,000 shares of Capricor Therapeutics stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $31.70, for a total value of $792,500.00. Following the completion of the sale, the chief financial officer owned 8,223 shares in the company, valued at $260,669.10. The trade was a 75.25% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Karimah Es Sabar sold 7,529 shares of Capricor Therapeutics stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $32.00, for a total value of $240,928.00. Following the completion of the sale, the director owned 7,529 shares of the company’s stock, valued at $240,928. This trade represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 172,529 shares of company stock valued at $5,302,440 in the last 90 days. 9.20% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Roth Mkm reissued a “buy” rating and issued a $38.00 target price on shares of Capricor Therapeutics in a research note on Friday, May 15th. HC Wainwright reissued a “buy” rating and issued a $60.00 target price on shares of Capricor Therapeutics in a research note on Wednesday, May 13th. B. Riley Financial boosted their target price on shares of Capricor Therapeutics from $50.00 to $63.00 and gave the company a “buy” rating in a research note on Friday, March 13th. Piper Sandler reissued an “overweight” rating and issued a $58.00 target price (up from $45.00) on shares of Capricor Therapeutics in a research note on Friday, March 13th. Finally, Cantor Fitzgerald set a $62.00 target price on shares of Capricor Therapeutics and gave the company an “overweight” rating in a research note on Friday, March 13th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $48.36.

Read Our Latest Research Report on Capricor Therapeutics

About Capricor Therapeutics

(Free Report)

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.